BioXcel Hid an FDA Investigation Into Its Alzheimer’s Drug Trial Now Investors Have a $9.75M Settlement
BioXcel Therapeutics Inc. and three of its executives agreed to pay $9,750,000 to settle a securities class action lawsuit alleging they concealed serious compliance problems in their Alzheimer’s drug clinical trial from investors. Investors who purchased BTAI stock between March 9, 2023, and June 28, 2023, may qualify for a cash payment. The deadline to…
